MXPA05013658A - Oligonucleotidos inmunomoduladores estabilizados. - Google Patents

Oligonucleotidos inmunomoduladores estabilizados.

Info

Publication number
MXPA05013658A
MXPA05013658A MXPA05013658A MXPA05013658A MXPA05013658A MX PA05013658 A MXPA05013658 A MX PA05013658A MX PA05013658 A MXPA05013658 A MX PA05013658A MX PA05013658 A MXPA05013658 A MX PA05013658A MX PA05013658 A MXPA05013658 A MX PA05013658A
Authority
MX
Mexico
Prior art keywords
immunostimulatory
oligonucleotides
immunomodulatory oligonucleotides
cpg
stabilized immunomodulatory
Prior art date
Application number
MXPA05013658A
Other languages
English (en)
Spanish (es)
Inventor
Rajendra K Pandey
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of MXPA05013658A publication Critical patent/MXPA05013658A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA05013658A 2003-06-11 2004-06-10 Oligonucleotidos inmunomoduladores estabilizados. MXPA05013658A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47760803P 2003-06-11 2003-06-11
US49903803P 2003-08-29 2003-08-29
US50427903P 2003-09-18 2003-09-18
PCT/US2004/018745 WO2005001055A2 (en) 2003-06-11 2004-06-10 Stabilized immunomodulatory oligonucleotides

Publications (1)

Publication Number Publication Date
MXPA05013658A true MXPA05013658A (es) 2006-03-02

Family

ID=33556397

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013658A MXPA05013658A (es) 2003-06-11 2004-06-10 Oligonucleotidos inmunomoduladores estabilizados.

Country Status (10)

Country Link
US (2) US8008267B2 (https=)
EP (2) EP1631576A4 (https=)
JP (2) JP4874801B2 (https=)
KR (1) KR101137572B1 (https=)
CN (1) CN102604957B (https=)
AU (2) AU2004252505B2 (https=)
CA (1) CA2528597C (https=)
ES (1) ES2569927T3 (https=)
MX (1) MXPA05013658A (https=)
WO (1) WO2005001055A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
AU9475001A (en) * 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2451974C (en) 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
GEP20094767B (en) * 2003-10-30 2009-09-10 Coley Pharm Group Inc C-class oligonucleotide analogs with enhanced immunostimulatory potency
CN101094594B (zh) * 2003-12-08 2012-08-15 海布里顿公司 通过基于小寡核苷酸的化合物调节免疫刺激性质
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CA2555105A1 (en) * 2004-02-20 2005-09-09 Hybridon, Inc. Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8076068B2 (en) * 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
WO2007031877A2 (en) * 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2007084237A2 (en) * 2005-12-20 2007-07-26 Idera Pharmaceuticals, Inc. Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications
US7786089B2 (en) * 2005-12-20 2010-08-31 Idera Pharmaceuticals, Inc. Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
US20080045473A1 (en) * 2006-02-15 2008-02-21 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
EP2021008B1 (en) * 2006-04-07 2015-12-02 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
EP2034015B1 (en) * 2006-05-31 2012-07-11 Toray Industries, Inc. Immunostimulatory oligonucleotide and pharmaceutical application thereof
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
MX2009006230A (es) * 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
CA2692161C (en) * 2007-07-09 2015-09-29 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds
KR20100053598A (ko) * 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
ES2534947T3 (es) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
PL2477980T3 (pl) 2009-09-15 2017-02-28 Taigen Biotechnology Co., Ltd. Inhibitory proteazy hcv
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2013012875A2 (en) 2011-07-18 2013-01-24 Mount Sinai School Of Medicine Bacterial rnas as vaccine adjuvants
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
KR101898177B1 (ko) * 2013-01-08 2018-09-12 이데라 파마슈티칼즈, 인코포레이티드 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
DE102015008536A1 (de) * 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
WO2017007027A1 (ja) * 2015-07-09 2017-01-12 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチド複合体
WO2017131124A1 (ja) 2016-01-26 2017-08-03 日産化学工業株式会社 一本鎖オリゴヌクレオチド
US11033569B2 (en) * 2016-07-06 2021-06-15 Sperovie Biosciences, Inc. Compounds,Compositions, and methods for the treatment of disease
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
JP7035065B2 (ja) * 2017-01-24 2022-03-14 シーティーエス・コーポレーション 車両用ブレーキペダルの位置センサ・力センサ組立体
CN110337495B (zh) 2017-02-06 2024-03-29 日产化学株式会社 单链寡核苷酸
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR20200099556A (ko) * 2017-12-15 2020-08-24 바이엘 애니멀 헬스 게엠베하 면역자극성 조성물
WO2020228606A1 (en) * 2019-05-10 2020-11-19 Microbio (Shanghai) Co., Ltd. Dimeric cpg oligonucleotides for use in modulating immune responses

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5495006A (en) * 1991-09-27 1996-02-27 Allelix Biopharmaceuticals, Inc. Antiviral polynucleotide conjugates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
TW244371B (https=) 1992-07-23 1995-04-01 Tri Clover Inc
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5921332A (en) 1997-12-29 1999-07-13 Sandvik Ab Apparatus for facilitating removal of a casing of an overburden drilling equipment from a bore
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
AU9475001A (en) * 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU3090102A (en) * 2000-12-14 2002-06-24 Gen Probe Inc Method and kit for enhancing the association rates of polynucleotides
JP4188687B2 (ja) * 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8153141B2 (en) * 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
EP1393745A1 (en) 2002-07-29 2004-03-03 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
EP1819365B1 (en) * 2004-12-09 2014-07-02 Alnylam Pharmaceuticals Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
US8383598B2 (en) * 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ES2544877T3 (es) * 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8426375B2 (en) * 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2021008B1 (en) * 2006-04-07 2015-12-02 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US8377898B2 (en) * 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CA2692161C (en) * 2007-07-09 2015-09-29 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds
KR20100053598A (ko) * 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제
JP5753382B2 (ja) * 2007-11-06 2015-07-22 アディウティーダ ファーマシューティカルズ ゲーエムベーハー 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
KR20110081338A (ko) * 2008-11-04 2011-07-13 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 5 발현의 조절
CA2752694A1 (en) * 2009-02-10 2010-08-19 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
CA2802721C (en) * 2010-06-25 2015-08-18 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
KR101985382B1 (ko) * 2010-11-19 2019-06-03 이데라 파마슈티칼즈, 인코포레이티드 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물

Also Published As

Publication number Publication date
AU2004252505A2 (en) 2005-01-06
ES2569927T3 (es) 2016-05-13
KR20060007444A (ko) 2006-01-24
KR101137572B1 (ko) 2012-05-30
CA2528597C (en) 2014-08-05
US20050026861A1 (en) 2005-02-03
US8946175B1 (en) 2015-02-03
JP2011200248A (ja) 2011-10-13
EP2371834B1 (en) 2016-02-17
CA2528597A1 (en) 2005-01-06
EP1631576A2 (en) 2006-03-08
EP1631576A4 (en) 2010-08-25
JP2007500018A (ja) 2007-01-11
AU2004252505A1 (en) 2005-01-06
WO2005001055A2 (en) 2005-01-06
CN102604957A (zh) 2012-07-25
US8008267B2 (en) 2011-08-30
AU2011200272A1 (en) 2011-02-17
JP4874801B2 (ja) 2012-02-15
CN102604957B (zh) 2015-10-07
AU2011200272B2 (en) 2011-12-22
AU2004252505B2 (en) 2010-10-28
EP2371834A1 (en) 2011-10-05
WO2005001055A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
MXPA05013658A (es) Oligonucleotidos inmunomoduladores estabilizados.
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
EP2752488A3 (en) Antisense design
WO2003008623A3 (en) Methylation analysis using nicking agents
EP1478656A4 (en) OLIGONUCLEOTIDE COMPOSITIONS HAVING IMPROVED EFFICIENCY
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
WO2003052132A3 (en) Linear and hairpin oligonucleotide analogues comprising intercalator pseudonucleotides
AU2002325538A1 (en) Nucleic acid amplification methods
WO2001051661A3 (en) A universal nucleic acid amplification system for nucleic acids in a sample
EP1445312A4 (en) PROCESS FOR INHIBITING GENE EXPRESSION
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1800691A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2003303395A8 (en) Target-dependent transcription using deletion mutants of n4 rna polymerase
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
EP1341909B8 (en) A method for in vitro molecular evolution of protein function
WO2003006677A3 (en) Multiplex nucleic acid reactions
WO2001044266A3 (en) Nucleic acid compounds and screening assays using the same
AU2002232521A1 (en) Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2002214041A1 (en) Diagnosis of diseases associated with the human c-mos gene
AU2001258274A1 (en) Synthetic oligonucleotides as inducers of erythroid differentiation
WO2006066154A3 (en) Casein kinase 2 antisense therapy

Legal Events

Date Code Title Description
FG Grant or registration